Both the U.S. Food and Drug Administration and the China National Medical Products Administration (NMPA) approved over ten indications of ICIs each for NSCLC clinical practice, including PD-1inhibitor (pembrolizumab/nivolumab/camrelizumab/tislelizumab/sintilimab), PD-L1 inhibitor (atezolizumab/durvalumab/sugemalimab), CTLA-4 inhibitor (ipilimumab). The gene discussed is CD274; the disease is non-small cell lung carcinoma.